Abstract: A treatment system includes a regulator implanted within a patient, a computing device storing at least one patient database associated with the patient in whom the regulator is implanted, and a data transfer device. The data transfer device provides bi-directional communication (e.g., voice communication) and a data exchange (e.g., a treatment history, a patient database, and operational instructions) between the regulator and the computing device. A programmer can obtain patient reports and/or default treatment values from the computing device based on the data exchange.

Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Abstract: A treatment system includes a regulator implanted within a patient, a computing device storing at least one patient database associated with the patient in whom the regulator is implanted, and a data transfer device. The data transfer device provides bi-directional communication (e.g., voice communication) and a data exchange (e.g., a treatment history, a patient database, and operational instructions) between the regulator and the computing device. A programmer can obtain patient reports and/or default treatment values from the computing device based on the data exchange.

Abstract: An analog-to-digital converter (ADC) circuit comprising two time-interleaved successive approximation register (SAR) ADCs. Each of the two time-interleaved SAR ADCs comprises a first stage SAR sub-ADC, a residue amplifier, a second stage SAR sub-ADC and a digital error correction logic. The residue amplifier is shared between the time-interleaved paths, has a reduced gain and operates in sub-threshold to achieve power effective design.

Abstract: This invention relates to bis-flavonoid compounds of formula Flavonoid-Linker-Y-Linker-Flavonoid, their synthesis and use for inhibiting multidrug resistance in chemotherapy and protozoan infection.

Abstract: The present invention provides an n-bits successive approximation register (SAR) analog-to-digital converting (ADC) circuit, comprising: an n-bits SAR control logic, a p-type capacitor network including a DACp array and a sampling capacitor CSp, an n-type capacitor network including a DACn array and a sampling capacitor CSn; and a comparator for comparing outputs from the p-type capacitor network and the n-type capacitor network, wherein a power supply and ground are directly connected to the p-type capacitor network and the n-type capacitor network without using reference voltages produced by a reference voltage generator. The n-bits SAR control logic comprises n shift registers, n bit registers, and a switching logic. The comparator comprises a first pre-amplifier, a second pre-amplifier and a dynamic latch. Alternative, the comparator comprises a four-input pre-amplifier and a dynamic latch.

Abstract: The present invention provides an n-bits successive approximation register (SAR) analog-to-digital converting (ADC) circuit, comprising: an n-bits SAR control logic, a p-type capacitor network including a DACp array and a sampling capacitor CSp, an n-type capacitor network including a DACn array and a sampling capacitor CSn; and a comparator for comparing outputs from the p-type capacitor network and the n-type capacitor network, wherein a power supply and ground are directly connected to the p-type capacitor network and the n-type capacitor network without using reference voltages produced by a reference voltage generator. The n-bits SAR control logic comprises n shift registers, n bit registers, and a switching logic. The comparator comprises a first pre-amplifier, a second pre-amplifier and a dynamic latch. Alternative, the comparator comprises a four-input pre-amplifier and a dynamic latch.

Abstract: The present invention provides an analog-to-digital converter (ADC) circuit comprising two time-interleaved successive approximation register (SAR) ADCs. Each of the two time-interleaved SAR ADCs comprises a first stage SAR sub-ADC, a residue amplifier, a second stage SAR sub-ADC and a digital error correction logic.

Abstract: A method of reducing tumor cell growth, the method including administering an effective amount of a compound having the formula:

Abstract: (?)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (?)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R11, R12, R13, R21, R22, R2, R3, and R4 are each independently selected from the group consisting of —H, and C1 to C10 acyloxyl group; and R5 is selected from the group consisting of —H, C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, C3-C7-cycloalkyl, phenyl, benzyl and C3-C7-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R11, R12, R13, R21, R22, R2, R3 and R4 is —H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth.

Abstract: The present disclosure relates to structurally defined imidazolium-type ionic oligomers of the formula: wherein n is an integer ranging from 1 to 20; A is N or m is an integer ranging from 1 to 5; X is selected from the group consisting of Br, OTf, CF3CO2, CH3CO2, BF4, PF6, NTf2, F, Cl and I; and R is selected from the group consisting of hydrogen and C1-10 alkyl. The imidazolium-type ionic oligomers lend themselves as soluble/solid supports for biopolymer synthesis.

Abstract: A treatment system includes a regulator implanted within a patient, a computing device storing at least one patient database associated with the patient in whom the regulator is implanted, and a data transfer device. The data transfer device provides bi-directional communication (e.g., voice communication) and a data exchange (e.g., a treatment history, a patient database, and operational instructions) between the regulator and the computing device. A programmer can obtain patient reports and/or default treatment values from the computing device based on the data exchange.

Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Abstract: A treatment system includes a regulator implanted within a patient, a computing device storing at least one patient database associated with the patient in whom the regulator is implanted, and a data transfer device. The data transfer device provides bidirectional communication (e.g., voice communication) and a data exchange (e.g., a treatment history, a patient database, and operational instructions) between the regulator and the computing device. A programmer can obtain patient reports and/or default treatment values from the computing device based on the data exchange.

Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Abstract: A zwitterionic phosphonium salt of Formula I: wherein n is 0 or 1; R is H or SO3; R? is selected from the group consisting of C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, phenyl, substituted phenyl, benzyl and C1-C10 alkoxy-carbonyl; R? is CX3 when n is O; and X is selected from the group consisting of F, Cl, Br and I. The zwitterionic phosphonium salts are useful reagents for the preparation of alkenes and acetals from the corresponding aldehyde.

Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.